|
CML Resource Center
CML Overview:
These links will take you to articles that provide general overviews of CML.
CML Treatment & Related Medications:
Gleevec/Glivec/STI571:
Leukemia Information:
Understanding Blood:
Bone Marrow Transplantation:
Clinical Trials:
Support & Psychology
Advocacy & Help
Insurance & Finances:
Journals & Publications:
Journal Articles:
- "Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia"
Leukemia (2001) 15, 62–68 (Adobe Acrobat required)
- "Chronic Myeloid Leukemia: STI571 Magnifies the Therapeutic Dilemma"
European Journal of Cancer 37 2001
- "Fatigue In Cancer: Like Pain, This Is A Symptom That Physicians Can And Should Manage"
British Medical Journal 2001;322:1560 ( 30 June )
- Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia
1 March 2001. Blood.
DNMTs were substantially overexpressed in leukemia cells in a leukemia type- and stage-specific manner. Up-regulated DNMTs may contribute to the pathogenesis of leukemia by inducing aberrant regional hypermethylation.
- Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
1 March 2001. Blood.
SCH66336 selectively inhibited the hematopoietic colony formation of primary human CML cells. As an oral, nontoxic compound with a mechanism of action distinct from that of ABL tyrosine kinase inhibition, FTI SCH66336 shows promise for the treatment of BCR/ABL-induced leukemia.
- Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
1 March 2001. Blood.
We conclude that farnesyl transferase inhibitor SCH66336 is able to revert early signs of leukemia and significantly prolongs survival in a murine ALL model.
- How I treat chronic graft-versus-host disease
1 March 2001. Blood.
Allogeneic stem cell transplantation (SCT) is now a commonplace procedure. Clinicians who care for patients with hematologic malignancies and aplastic anemia are almost certain to follow up patients after SCT. This review is intended to help clinicians observe patients for probably the most important late complication of SCT, chronic graft-versus-host disease (GVHD). It reviews the pathophysiology, risk factors, clinical manifestations, evaluation, treatment, and supportive care of chronic GVHD.
- Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.
February 2001. Experimental Hematology.
Our aim was to expand these searches by looking for mutations in the death domains of FAS, FADD, TNFR, TRADD, and RIP, in the promoter region of FAS, and in the protease domain of caspase 10, in a larger variety of hematological malignancies, some of which express an apoptosis-resistant phenotype, including chronic myelogenous leukemia.
- "Applicability of an Absolute Quantitative Procedure to Monitor Intra-Individual BCR/ABL Transcript Kinetics in Clinical Samples from Chronic Myelogenous Leukemia Patients"
Int. J. Cancer: 86, 741–746 (2000)
"Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-a"
Leukemia (2000) 14, 2064–2069 (Adobe Acrobat required)
- "MINI-REVIEW: Detection and quantification of residual disease in chronic myelogenous leukemia"
Leukemia (2000) 14, 998–1005 (Adobe Acrobat required)
- Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
1 November 2000. Blood (abstract only).
- New treatment approaches for chronic myelogenous leukemia
October 2000. Semin Oncol (abstract only).
- Science, Medicine & the Future: Stem Cell Transplantation
August 2000.
A clinical review from the British Medical Journal.
- Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia"
Leukemia (1999) 13, 999–1008 (Adobe Acrobat required)
- Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex"
Bone Marrow Transplantation, (1999) 24, 1057–1063 (Adobe Acrobat required)
- "Management of Chronic Myeloid Leukemia
During Pregnancy With Leukapheresis"
Journal of Clinical Apheresis 14:42–44 (1999)
- The Prospects for Antisense Therapy
1999. Hospital Practice.
On several fronts, including hematologic malignancies, the concept has reached clinical trials, where appreciation of the in vivo hurdles is leading to new approaches for delivery of this new magic bullet.
- Drug therapy for chronic myeloid leukemia
August 1999. National Guideline Clearinghouse.
- Killing Cancer
- "Survival With Chronic Myelogenous Leukemia: The Outcome of a Patient Who Had One of the Longest Survivals"
Oncology 1998;55:607 Letter to the Editor
May 1998. U.S. News online.
New drugs can cure mice, thanks to advances in understanding the disease's basic biology. But cures for people are still years away.
- Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia
1998. Journal of Clinical Oncology.
To determine, in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on interferon alfa (IFNalpha), whether combining pretreatment characteristics and early response profiles would distinguish patients with differential benefits that would allow better decisions on subsequent therapy.
- A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa
1998. Journal of the National Cancer Institute.
A meta-analysis was conducted to develop a reliable prognostic scoring system for estimation of survival of patients with CML treated with interferon alfa.
- HLA Gene and Haplotype Frequencies in the North American Population: The National Marrow Donor Program Donor Registry
1997. American Society for Histocompatibility and Immunogenetics.
Information about gene frequencies and haplotypes.
- Leukemia Support Groups: How Are They Doing?
September/October 1997. Cancer Control Journal.
An inside look at the setup and effectiveness of support groups.
- Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-alpha Therapy
February 1995. Annals of Internal Medicine. Hagop M. Kantarjian, MD; Terry L. Smith, MS; Susan O'Brien, MD; Miloslav Beran, MD, PhD; Sherry Pierce, RN; Moshe Talpaz, MD; and the Leukemia Service.
Cancer Centers:
Associations:
General Cancer Resources:
Give me a holler
This site was last updated on Dec. 18, 2001
Copyright © 2000-2001 CMLSupport.com. All rights reserved.
The fine print: These contents may not be reproduced in whole or in part without the express written permission of the author. Or she will beat you up and stuff. This site is best viewed with Internet Explorer, but we won't stop you from using another Web browser. Congratulations if you've read all of this! (But we're sorry to say, the person before you got our last cash prize!)
|
